Sarepta Therapeutics (NASDAQ:SRPT) announced Friday that the company and its partner Roche (OTCQX:RHHBY) expect to provide EU ...

Sarepta Therapeutics (NASDAQ:SRPT – Get Free Report) was upgraded by investment analysts at HC Wainwright from a “sell” ...

Shares of Sarepta Therapeutics (NASDAQ:SRPT) fell in the premarket on Thursday following news regarding a clinical hold ...

RBC Capital analyst Brian Abrahams maintained a Hold rating on Sarepta Therapeutics (SRPT – Research Report) on April 3 and set a price target ...

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards ...

Sarepta Therapeutics (NASDAQ:SRPT – Get Free Report) was downgraded by stock analysts at Royal Bank of Canada from an ...

Shares of biotech company Sarepta Therapeutics (NASDAQ:SRPT) fell 10.8% in the afternoon session after RBC analyst Brian ...

NEW YORK, NY / ACCESS Newswire / April 3, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers ...

It has been about a month since the last earnings report for Sarepta Therapeutics (SRPT). Shares have lost about 30.3% in that time frame, underperforming the S&P 500. Will the recent negative ...

In a report released today, Tazeen Ahmad from Bank of America Securities maintained a Buy rating on Sarepta Therapeutics (SRPT – Research ...

Shares of some U.S. biotechnology companies including Moderna (MRNA) plunged on Monday after reports that the top vaccine ...